Proteomics International Laboratories Ltd
ASX:PIQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Proteomics International Laboratories Ltd
Total Equity
Proteomics International Laboratories Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
Total Equity
AU$7.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Genetic Technologies Ltd
ASX:GTG
|
Total Equity
-AU$2.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Anteotech Ltd
ASX:ADO
|
Total Equity
AU$2m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-13%
|
|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Total Equity
AU$105.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Cryosite Ltd
ASX:CTE
|
Total Equity
AU$3.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
344%
|
CAGR 10-Years
0%
|
|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Total Equity
AU$28.1m
|
CAGR 3-Years
35%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
Proteomics International Laboratories Ltd
Glance View
Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2015-04-16. The firm is engaged in predictive diagnostics and bio-analytical services. The firm specializes in proteomics, the study of the structure and function of proteins. The firm focuses on developing and commercializing diagnostic tests for chronic diseases. The firm operates in three business units unified by a technology platform: PromarkerD, Diagnostics and Analytical Services. PromarkerD is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes. Diagnostics includes Promarker platform, used to discover, verify, and analytically validate the panel of protein biomarkers for diabetic kidney disease. Analytical Services includes proteomics-based technology platform, used to test, and validate the protein composition of a wide and varied range of products.
See Also
What is Proteomics International Laboratories Ltd's Total Equity?
Total Equity
7.4m
AUD
Based on the financial report for Dec 31, 2025, Proteomics International Laboratories Ltd's Total Equity amounts to 7.4m AUD.
What is Proteomics International Laboratories Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
-2%
Over the last year, the Total Equity growth was 36%. The average annual Total Equity growth rates for Proteomics International Laboratories Ltd have been 1% over the past three years , -2% over the past five years .
